FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3169643008> ?p ?o ?g. }

• W3169643008 endingPage "258" @default.
• W3169643008 startingPage "257" @default.
• W3169643008 abstract "We have read with interest the letter to you from Dr Lockley and colleagues [ [1] Lockley M, Stoneham S, Shamash J, et al. Letter re: ‘Can we replace adjuvant chemotherapy with surveillance for stage IA-C immature ovarian teratomas of any grade? an international multicenter analysis’. Google Scholar ] published in response to our manuscript entitled ‘Can we replace adjuvant chemotherapy with surveillance for stage IA-C immature ovarian teratomas of any grade? an international multicenter analysis’ that supports surveillance rather than adjuvant chemotherapy in stage I immature teratomas (ITs). This paper was based on the evaluation of the outcomes of 108 patients with pure ITs, as a result of an international collaboration [ [2] Bergamini A. Sarwar N. Ferrandina G. et al. Can we replace adjuvant chemotherapy with surveillance for stage IA-C immature ovarian teratomas of any grade? an international multicenter analysis. Eur J Canc. 2020 Sep; 137 (Epub 2020 Aug 4): 136-143https://doi.org/10.1016/j.ejca.2020.06.033 Abstract Full Text Full Text PDF PubMed Scopus (4) Google Scholar ]. Dr Lockley and colleagues have previously published an interesting retrospective series on a diverse set of patients with malignant ovarian germ-cell tumours (MOGCTs) including 42 ITs [ [3 ] Newton C. Murali K. Ahmad A. et al. A multicentre restrospective cohort study of ovarian germ cell tumors: evidence for chemotherapy de-escalation and alignment of pediatric and adult practice. Eur J Canc. 2019; 113: 19-27 Abstract Full Text Full Text PDF PubMed Scopus (24) Google Scholar ]. Their and other retrospective analyses found that disease recurrence was not significantly reduced by adjuvant chemotherapy in this patient setting, although patient numbers were low [ 3 Newton C. Murali K. Ahmad A. et al. A multicentre restrospective cohort study of ovarian germ cell tumors: evidence for chemotherapy de-escalation and alignment of pediatric and adult practice. Eur J Canc. 2019; 113: 19-27 Abstract Full Text Full Text PDF PubMed Scopus (24) Google Scholar , 4 Mangili G. Scarfone G. Gadducci A. et al. Is adjuvant chemotherapy indicated in stage I pure immature ovarian teratoma (IT)? A multicentre Italian trial in ovarian cancer (MITO-9). Gynecol Oncol. 2010; 119: 48-52 Abstract Full Text Full Text PDF PubMed Scopus (50) Google Scholar , 5 Pashankar F. Hale J.P. Dang H. et al. Is adjuvant chemotherapy indicated in ovarian immature teratomas? A combined data analysis from the Malignant Germ Cell Tumor International Collaborative. Cancer. 2016; 122: 230-237 Crossref PubMed Scopus (68) Google Scholar ]. Can we replace adjuvant chemotherapy with surveillance for stage IA-C immature ovarian teratomas of any grade? an international multicenter analysisEuropean Journal of CancerVol. 137PreviewThe role of surveillance after surgery for stage IA-C grade 2 (G2) or grade 3 (G3) immature teratomas (ITs) is controversial with many guidelines advocating adjuvant chemotherapy. Here, we investigate the safety of surveillance in stage IA-C G1-3 ITs. Full-Text PDF Re: ‘Can we replace adjuvant chemotherapy with surveillance for stage IA-C immature ovarian teratomas of any grade? An international multicenter analysis’European Journal of CancerVol. 152PreviewThe article by Bergamini et al. [1] adds to the growing body of evidence supporting surveillance, rather than adjuvant chemotherapy, in the postoperative management of ovarian immature teratomas (IT). Postop surveillance is established for paediatric IT [2–5] yet international guidelines continue to recommend adjuvant chemotherapy for nearly all adults [6,7]. The authors highlight studies suggesting that postoperative surveillance may also be safe for adult patients [8], particularly in stage I disease [9], but rightly point out that clinical evidence is extremely sparse. Full-Text PDF" @default.
• W3169643008 created "2021-06-22" @default.
• W3169643008 creator A5002158178 @default.
• W3169643008 creator A5004164286 @default.
• W3169643008 creator A5004186145 @default.
• W3169643008 creator A5023273014 @default.
• W3169643008 creator A5024920201 @default.
• W3169643008 creator A5030229940 @default.
• W3169643008 creator A5031050958 @default.
• W3169643008 creator A5031310389 @default.
• W3169643008 creator A5032691424 @default.
• W3169643008 creator A5042255432 @default.
• W3169643008 creator A5054452892 @default.
• W3169643008 creator A5060103872 @default.
• W3169643008 creator A5066769987 @default.
• W3169643008 creator A5083659627 @default.
• W3169643008 date "2021-07-01" @default.
• W3169643008 modified "2023-10-01" @default.
• W3169643008 title "Response to letter entitled: Re: Can we replace adjuvant chemotherapy with surveillance for stage IA-C immature ovarian teratomas of any grade? An international multicenter analysis" @default.
• W3169643008 cites W1765381491 @default.
• W3169643008 cites W2011815192 @default.
• W3169643008 cites W2934884174 @default.
• W3169643008 cites W3047516807 @default.
• W3169643008 doi "https://doi.org/10.1016/j.ejca.2021.05.002" @default.
• W3169643008 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34112565" @default.
• W3169643008 hasPublicationYear "2021" @default.
• W3169643008 type Work @default.
• W3169643008 sameAs 3169643008 @default.
• W3169643008 citedByCount "1" @default.
• W3169643008 countsByYear W31696430082022 @default.
• W3169643008 crossrefType "journal-article" @default.
• W3169643008 hasAuthorship W3169643008A5002158178 @default.
• W3169643008 hasAuthorship W3169643008A5004164286 @default.
• W3169643008 hasAuthorship W3169643008A5004186145 @default.
• W3169643008 hasAuthorship W3169643008A5023273014 @default.
• W3169643008 hasAuthorship W3169643008A5024920201 @default.
• W3169643008 hasAuthorship W3169643008A5030229940 @default.
• W3169643008 hasAuthorship W3169643008A5031050958 @default.
• W3169643008 hasAuthorship W3169643008A5031310389 @default.
• W3169643008 hasAuthorship W3169643008A5032691424 @default.
• W3169643008 hasAuthorship W3169643008A5042255432 @default.
• W3169643008 hasAuthorship W3169643008A5054452892 @default.
• W3169643008 hasAuthorship W3169643008A5060103872 @default.
• W3169643008 hasAuthorship W3169643008A5066769987 @default.
• W3169643008 hasAuthorship W3169643008A5083659627 @default.
• W3169643008 hasConcept C121608353 @default.
• W3169643008 hasConcept C126322002 @default.
• W3169643008 hasConcept C143998085 @default.
• W3169643008 hasConcept C146357865 @default.
• W3169643008 hasConcept C151730666 @default.
• W3169643008 hasConcept C167135981 @default.
• W3169643008 hasConcept C168563851 @default.
• W3169643008 hasConcept C2776694085 @default.
• W3169643008 hasConcept C2776938808 @default.
• W3169643008 hasConcept C29456083 @default.
• W3169643008 hasConcept C2992435398 @default.
• W3169643008 hasConcept C3018227240 @default.
• W3169643008 hasConcept C530470458 @default.
• W3169643008 hasConcept C71924100 @default.
• W3169643008 hasConcept C72563966 @default.
• W3169643008 hasConcept C86803240 @default.
• W3169643008 hasConceptScore W3169643008C121608353 @default.
• W3169643008 hasConceptScore W3169643008C126322002 @default.
• W3169643008 hasConceptScore W3169643008C143998085 @default.
• W3169643008 hasConceptScore W3169643008C146357865 @default.
• W3169643008 hasConceptScore W3169643008C151730666 @default.
• W3169643008 hasConceptScore W3169643008C167135981 @default.
• W3169643008 hasConceptScore W3169643008C168563851 @default.
• W3169643008 hasConceptScore W3169643008C2776694085 @default.
• W3169643008 hasConceptScore W3169643008C2776938808 @default.
• W3169643008 hasConceptScore W3169643008C29456083 @default.
• W3169643008 hasConceptScore W3169643008C2992435398 @default.
• W3169643008 hasConceptScore W3169643008C3018227240 @default.
• W3169643008 hasConceptScore W3169643008C530470458 @default.
• W3169643008 hasConceptScore W3169643008C71924100 @default.
• W3169643008 hasConceptScore W3169643008C72563966 @default.
• W3169643008 hasConceptScore W3169643008C86803240 @default.
• W3169643008 hasLocation W31696430081 @default.
• W3169643008 hasLocation W31696430082 @default.
• W3169643008 hasOpenAccess W3169643008 @default.
• W3169643008 hasPrimaryLocation W31696430081 @default.
• W3169643008 hasRelatedWork W167319750 @default.
• W3169643008 hasRelatedWork W1987468340 @default.
• W3169643008 hasRelatedWork W2030370704 @default.
• W3169643008 hasRelatedWork W2048236688 @default.
• W3169643008 hasRelatedWork W2801741755 @default.
• W3169643008 hasRelatedWork W2805734855 @default.
• W3169643008 hasRelatedWork W2954181125 @default.
• W3169643008 hasRelatedWork W3015427122 @default.
• W3169643008 hasRelatedWork W4220939315 @default.
• W3169643008 hasRelatedWork W4254366463 @default.
• W3169643008 hasVolume "152" @default.
• W3169643008 isParatext "false" @default.
• W3169643008 isRetracted "false" @default.
• W3169643008 magId "3169643008" @default.
• W3169643008 workType "article" @default.